tHEORetically speaking

HealthEconomics.com

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

read less

ScienceScience

Start Here

tHEORetically speaking: How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications

tHEORetically speaking: How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications

In this episode of tHEORetically speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients' experiences and inform access, treatment, and condition management.Real-world data provides an opportunity to understand what happens to patients, but there are limitations to the insights we can generate using traditional analysis techniques alone. At OM1, our PhenOM technology uses AI to isolate subtle signals in real-world data associated with outcomes we care about - diagnoses, treatment response, and future risks. The insights we derive integrate into our existing patient journeys to answer questions we couldn't without this technology, including who remains undiagnosed or misdiagnosed, and how patient subcohorts take different trajectories within the same broader condition.To learn more, click here.

Episodes

tHEORetically speaking: How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications

tHEORetically speaking: How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications

In this episode of tHEORetically speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients' experiences and inform access, treatment, and condition management.Real-world data provides an opportunity to understand what happens to patients, but there are limitations to the insights we can generate using traditional analysis techniques alone. At OM1, our PhenOM technology uses AI to isolate subtle signals in real-world data associated with outcomes we care about - diagnoses, treatment response, and future risks. The insights we derive integrate into our existing patient journeys to answer questions we couldn't without this technology, including who remains undiagnosed or misdiagnosed, and how patient subcohorts take different trajectories within the same broader condition.To learn more, click here.

tHEORetically speaking: Clinical Outcomes Assessments and Training

tHEORetically speaking: Clinical Outcomes Assessments and Training

In this episode of tHEORetically Speaking, join Kelly Lipman, Heather Dickerson, and Ryan Murphy from ICON, who answer questions from a recent webinar on the dynamic landscape of clinical outcomes assessments, examining their historical significance, current uses and best practices, and making a case for greater standardization in their implementation.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: EU HTA Joint Clinical Assessments

tHEORetically speaking: EU HTA Joint Clinical Assessments

In this episode of tHEORetically Speaking, join Dr. Rosemary Jose, Dr. Sonja Kroep, and Nick Halfpenny from OPEN Health, Dr. Ansgar Hebborn from Roche, and James Ryan from AstraZeneca, who answer questions from a recent webinar on several policy aspects regarding the current challenges and implications of the EU Health Technology Assessment (HTA) regulation.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Cell & Gene Therapies

tHEORetically speaking: Cell & Gene Therapies

In this episode of tHEORetically Speaking, join Dr. Pamela Landsman-Blumberg, Amanda O’Hora, and Ajay Keshava from Magnolia Market Access, who answer questions from a recent webinar on how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Patient-Centered Real-World Evidence in Rare Diseases

tHEORetically speaking: Patient-Centered Real-World Evidence in Rare Diseases

In this episode of tHEORetically Speaking, join Drs. Megan Gower and Edward Chou from Takeda, and Richard Tsai, MS from Inspire, who answer questions from a recent webinar on the challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases, to support clinical development through commercial post-approval.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Real-World Evidence Generation with Disease Registries

tHEORetically speaking: Real-World Evidence Generation with Disease Registries

In this episode of tHEORetically Speaking, join Drs. Javier Cid, Nahila Justo, and Delphine Saragoussi from Evidera and PPD, who answer questions from a recent webinar on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Clinical Outcome Assessment (COA) Translations

tHEORetically speaking: Clinical Outcome Assessment (COA) Translations

In this episode of tHEORetically speaking, join Christelle Giroudet, MA and Ana Alvarez, MA, COA Linguistic Validation Leaders with ICON, as they highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Between Two Scientists - New Types of Data

tHEORetically speaking: Between Two Scientists - New Types of Data

This episode of tHEORetically Speaking is the third installment of Panalgo’s ‘Between Two Scientists’, featuring host Meg Richards, Executive Director of Solutions at Panalgo, who chats with Norstella’s General Manager of RWD, Ted Search, General Manager of RWD at Norstella about new types of unstructured real-world data and the challenges of incorporating them with structured data.Have a listen to the second ‘Between Two Scientists’ podcast which covered the privacy certification of linked data with Bobby Samuels of Datavant.For more information or to access other resources, click here.

tHEORetically speaking: Total System Value™ - A DYNAMIC APPROACH TO VALUE DEMONSTRATION

tHEORetically speaking: Total System Value™ - A DYNAMIC APPROACH TO VALUE DEMONSTRATION

HEOR Ltd. have been working on an exciting new framework called Total System Value™. This episode of tHEORetically speaking features their CEO Phil McEwan and CGO Jeff Anderson to talk to us about this dynamic approach to value demonstration. Total System Value™ (TSV)™ is a new, dynamic framework designed to assess the value of adopting a new technology or policy initiative at a population level. For more information or to access other resources, click here.

tHEORetically speaking: Between Two Scientists - Labeling and Certifying your Varietal Data Blend

tHEORetically speaking: Between Two Scientists - Labeling and Certifying your Varietal Data Blend

This episode of tHEORetically Speaking is the second installment of Panalgo's 'Between Two Scientists', featuring host Meg Richards, Executive Director of Solutions at Panalgo, and Bobby Samuels, General Manager of Privacy Hub at Datavant.In the first episode of ‘Between Two Scientists', we talked about data linkages and the need to certify the linked data before they can be used for research. In this episode, we’re picking up the data certification thread. Like the first episode, this one is also to wine-making.For more information or to access other resources, click here.

tHEORetically speaking: How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&D

tHEORetically speaking: How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&D

The hype around AI is finally translating into real-world value, and we are seeing broader adoption of real-world data in Dermatology. This episode of tHEORetically Speaking features Dr. Stefan Weiss, Managing Director of Dermatology and Dr. Joseph Zabinski, Managing Director of AI and Personalized Medicine at OM1, who discuss the path to personalized medicine and AI-powered clinical decision support in dermatology.For more information or to access other resources, click here.

tHEORetically speaking: The Future of Diversity in Clinical Trials: Real-World Evidence

tHEORetically speaking: The Future of Diversity in Clinical Trials: Real-World Evidence

This episode of tHEORetically Speaking features real-world evidence experts Alexandrina Balanean, Parisa Asgarisabet, and Danielle Gentile from Cardinal Health discussing the problems caused by lack of diverse representation in clinical trials.The underrepresentation of disproportionately burdened groups limits information on therapeutic response, safety, and efficacy to a small subset of the population—which tends to be healthier, more well-educated, and financially advantaged. However, recent findings show that real-world evidence (RWE) may be able to help with this underrepresentation. Listen in to learn more about these findings and what it may mean for the future of RWE.For more information or to access other resources, click here.

tHEORetically speaking: Between Two Scientists - Data Linkage

tHEORetically speaking: Between Two Scientists - Data Linkage

This episode of tHEORetically Speaking features our host Meg Richards, Executive Director of Solutions at Panalgo, who will be speaking with Erik Maul, Senior Director of Data Partnerships at Panalgo about data linkage.The healthcare and life sciences industries are currently experiencing transformative times of growth. The explosion of real-world data, new regulatory programs and frameworks, and a focus on AI and machine learning are only a few of the factors contributing to this rapidly evolving landscape. In this podcast – we’re aiming to illuminate these catalysts of change by talking to the experts themselves. From tHEORetically Speaking, this is Episode 1 "Like Making a Fine, Blended Wine from Varietal Data Sources" of the Between Two Scientists series by Panalgo.For more information or to access other resources, click here.

tHEORetically speaking: Detecting and Decoding Alzheimer's with Real-World Data

tHEORetically speaking: Detecting and Decoding Alzheimer's with Real-World Data

The landscape for Alzheimer's disease is rapidly changing. This episode of tHEORetically speaking features Dr. Carl Marci from OM1 and Dr. Luke Stoeckel from NIA, as they discuss the critical need for earlier detection leading to potentially life changing earlier interventions.For more information or to access other resources, click here.

tHEORetically speaking: Leveraging Real-World Data for Precision Obesity Treatment

tHEORetically speaking: Leveraging Real-World Data for Precision Obesity Treatment

In this episode of tHEORetically speaking, Gary Curhan, Chief Medical Officer and Jessica Paulus, Vice President of Research at OM1, as they answer questions on Leveraging Real-World Data for Precision Obesity Treatment. For more information or access other resources, click here.

tHEORetically speaking: Medicare and Medicaid Services Market Pricing

tHEORetically speaking: Medicare and Medicaid Services Market Pricing

In this episode of tHEORetically Speaking, join ICON experts Mark McCoy, Dr. Earlene Biggs, Bruce Capobianco, Dr. Tanja Obradovic, Ki Park, and Nancy Risebroughas they answer questions on the Centers for Medicare and Medicaid Services’ negotiations on the fair market prices for Medicare Part D products.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Medicare Data for RWD Analysis

tHEORetically speaking: Medicare Data for RWD Analysis

In this episode of tHEORetically Speaking, join Dr. Eunice Chang and Dr. Michael Broder from PHAR, and Mitra Corral from Genentechas they answer questions on the how and why use of Medicare data for conducting various types of RWD analysis is important.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: The Benefits of Linking SDOH Data with Other Real-World Data

tHEORetically speaking: The Benefits of Linking SDOH Data with Other Real-World Data

In this episode of tHEORetically speaking, join Dr. Pamela Landsman-Blumberg from Magnolia Market Access and Dr. Rick Chapman from Innovation and Value Initiativeas they answer questions on the importance of social determinants of health (SDOH) and describe the benefits of linking SDOH data with other real-world data when conducting health economics and outcomes research (HEOR).For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Improving the Representativeness of Research

tHEORetically speaking: Improving the Representativeness of Research

In this episode of tHEORetically speaking, join Dr. Bruce Feinberg, Dr. Danielle Gentile, Dr. Parisa Asgarisabet, and Alexandrina Balanean from Cardinal Health as they answer questions on the economic impact and role of real world evidence (RWE) in improving representativeness of research.For more information, to watch the webinar, or access other resources, click here.

tHEORetically speaking: Literature Reviews and Global Value Dossiers

tHEORetically speaking: Literature Reviews and Global Value Dossiers

In this episode of tHEORetically speaking, join Gillian Sibbring, Sue O’Leary, Ben Rousseau, Patti Peeples, and Rachel Forrest as they answer questions on systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.For more information, to watch the webinar, or access other resources, click here.